久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國(guó)Agios Pharmaceuticals 
Agios Pharmaceuticals是一家獨(dú)立的未公開上市生物制藥公司，致力于在新興的癌代謝領(lǐng)域發(fā)現(xiàn)并開發(fā)出新型治療方案。為了支持并推進(jìn)這些努力，Agios已經(jīng)建立了一個(gè)集生物學(xué)、代謝組學(xué)、生物化學(xué)和信息學(xué)于一體的強(qiáng)大平臺(tái)，為靶標(biāo)與生物標(biāo)記的確定提供支持。

迄今為止，Agios已經(jīng)組建了一支世界級(jí)科研團(tuán)隊(duì)，建立了規(guī)模最大的癌代謝研究實(shí)驗(yàn)室，并創(chuàng)立了一個(gè)致力于研究新型癌癥療法的新興復(fù)方藥開發(fā)渠道。該公司的創(chuàng)始人與科研顧問都是癌代謝領(lǐng)域的核心思想領(lǐng)導(dǎo)者，負(fù)責(zé)該領(lǐng)域的主要進(jìn)展、見解與發(fā)現(xiàn)工作。Agios Pharmaceuticals位于馬薩諸塞州坎布里奇，由Third Rock、Flagship和ARCH Venture Partners提供資金。
首家致力于研發(fā)通過生化代謝的方式來阻止癌細(xì)胞的擴(kuò)散，并最終治愈的生物醫(yī)藥公司Agios Pharmaceuticals宣布，其獲得了3300萬美元的A輪融資。 資金將用于搭建一個(gè)平臺(tái)，以加速治療癌癥藥物的研發(fā)過程。Third Rock Ventures、Flagship Ventures、ARCH Venture Partners聯(lián)合主導(dǎo)了此次投資。

Agios is a biopharmaceutical company at the forefront of one of the most exciting new areas of cancer research: cancer metabolism. Cancer metabolism represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth.

Over the past few decades cancer research has focused on complex tumor signaling originating from oncogenes and tumor suppressor genes; the new field of cancer metabolism shows many of these signals are actually modulating the metabolic functioning of cancer cells. As a result, the intersection of these two fields of research — cancer and metabolism — represents an important and novel approach to treating cancer. The new understanding of a fundamental mechanism of cancer survival represents a new, powerful Achilles’ Heel to target this deadly disease.

Agios Pharmaceuticals is developing a deep pipeline of drug candidates that disrupt the growth and survival of cancer based on unique insights of the founders, scientific advisory board as well as building on decades of research in the fields of oncology and metabolism.

The company’s initial focus is cancer, particularly targeting three key metabolic pathways — glycolysis (sugar metabolism), fatty acid metabolism, and autophagy (self-metabolism). Agios’ primary focus is in oncology, but the company’s platform will also be applicable to other therapeutics areas including autoimmune, inflammatory and neurological diseases.